A PYMNTS Company

Multinational: Without new CEO, Teva Pharmaceuticals may look to merge

By  |  November 19, 2013

As Israel-based Teva Pharmaceuticals struggles to recuperate losses after one f its worst yearly performances, reports say the company may look to merge with counterparts within the US or Canada if it cannot find a new chief executive officer.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The generic drug maker may look to strike a deal with US-based Mylan Inc. or Canada-based Valeant Pharmaceuticals International. The company remains under threat, however, of a takeover by an activist investor, according to Matric Asset Advisors.

    The company remains without a CEO as their last resigned last October; analysts are now awaiting the company’s next move.

    A recently Supreme Court ruling places Teva in the line of fire for competition from rival generic drug makers producing Copaxone, a treatment for multiple sclerosis.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.